MYC cofactors: Molecular switches controlling diverse biological outcomes

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 9, 2014, Pages

  Hann, Stephen R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CYCLIN G2; HISTONE DEACETYLASE 1; HISTONE H4; INTEGRIN; MYC PROTEIN; NEUROTROPHIN RECEPTOR P75; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN KINASE PIM 1; RNA POLYMERASE;

APOPTOSIS; ARTICLE; BIOLOGICAL FUNCTIONS; CARCINOGENESIS; CELL PROLIFERATION; CELLS BY BODY ANATOMY; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; ENZYME ACTIVATION; GENE TARGETING; HISTONE ACETYLATION; PROTEIN PROCESSING; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; ANIMAL; CELL TRANSFORMATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84923832213     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a014399     Document Type: Article

References (191)

1. Adhikary S, Eilers M. 2005. Transcriptional regulation and transformation byMyc proteins. Nat Rev Mol Cell Biol 6: 635–645.
2. Agrawal P, Yu K, Salomon AR, Sedivy JM. 2010. Proteomic profiling of Myc-associated proteins. Cell Cycle 9: 4908–4921.
3. Alitalo K, Ramsay G, Bishop JM, Pfeifer SO, Colby WW, Levinson AD. 1983. Identification of nuclear proteins encoded by viral and cellular myc oncogenes. Nature 306: 274–277.
4. Arabi A, Wu S, Ridderstrale K, Bierhoff H, Shiue C, Fatyol K, Fahlen S, Hydbring P, Soderberg O, Grummt I, et al. 2005. c-Myc associates with ribosomalDNA and activates RNA polymerase I transcription. Nat Cell Biol 7: 303–310.
5. Arvanitis C, Felsher DW. 2006.Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol 16: 313–317.
6. Barrett J, Birrer MJ, Kato GJ, Dosaka-Akita H, Dang CV. 1992. Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells. Mol Cell Biol 12: 3130–3137.
7. Benassayag C, Montero L, Colombie N, Gallant P, Cribbs D, Morello D. 2005. Human c-Myc isoforms differentially regulate cell growth and apoptosis in Drosophila melanogaster. Mol Cell Biol 25: 9897–9909.
8. Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M, Zupi G, Biroccio A. 2006. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell 21: 509–519.
9. Blackwell TK, Huang J, Ma A, Kretzner L, Alt FW, Eisenman RN, Weintraub H. 1993. Binding of myc proteins to canonical and noncanonical DNA sequences. Mol Cell Biol 13: 5216–5224.
10. Boone DN, Qi Y, Li Z, Hann SR. 2011. Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism. Proc Natl Acad Sci 108: 632–637.
11. Bouchard C, Dittrich O, Kiermaier A, Dohmann K, Menkel A, Eilers M, Luscher B. 2001. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev 15: 2042–2047.
12. Bouchard C, Marquardt J, Bras A, Medema RH, Eilers M. 2004. Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. EMBO J 23: 2830–2840.
13. Brés V, Yoh SM, Jones KA. 2008. The multi-tasking P-TEFb complex. Curr Opin Cell Biol 20: 334–340.
14. Bush A, Mateyak M, Dugan K, Obaya A, Adachi S, Sedivy J, Cole M. 1998. c-myc null cells misregulate cad and gadd45 but not other proposed c-Myc targets. Genes Dev 12: 3797–3802.
15. Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D, Schleker T, Perna D, Tronnersjo S, Murga M, et al. 2010. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol 12: 54-59; 1–14.
16. Chase A, Cross NC. 2011. Aberrations of EZH2 in cancer. Clin Cancer Res 17: 2613–2618.
17. Chen D, Yoon JB, Gu W. 2010. Reactivating the ARF-p53 axis in AML cells by targeting ULF. Cell Cycle 9: 2946–2951.
18. Chen D, Kon N, Zhong J, Zhang P, Yu L, Gu W. 2013a. Differential effects on ARF stability by normal versus oncogenic levels of c-Myc expression. Mol Cell 51: 46–56.
19. Chen L, Wei T, Si X, Wang Q, Li Y, Leng Y, Deng A, Chen J, Wang G, Zhu S, et al. 2013b. Lysine acetyltransferase GCN5 potentiates the growth of non-small cell lung cancer via promotion of E2F1, cyclin D1, and cyclin E1 expression. J Biol Chem 288: 14510–14521.
20. Cheng SW, Davies KP, Yung E, Beltran RJ, Yu J, Kalpana GV. 1999. c-MYC interactswith INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet 22: 102–105.
21. Chevillard-Briet M, Quaranta M, Grezy A, Mattera L, Courilleau C, Philippe M, Mercier P, Corpet D, Lough J, Ueda T, et al. 2013. Interplay between chromatin-modifyig enzymes controls colon cancer progression through Wnt signaling. Hum Mol Genet doi: 10.1093/hmg/ddt604.
22. Choi SH, Wright JB, Gerber SA, Cole MD. 2010. Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells. Genes Dev 24: 1236–1241.
23. Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, Nucifero P, Pacchiana G, Capra M, Christensen J, et al. 2009. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res 69: 8491–8498.
24. Ciurciu A, Komonyi O, Pankotai T, Boros IM. 2006. The Drosophila histone acetyltransferase Gcn5 and transriptional adaptor Ada2a are involved in nucleosomal histone H4 acetylation. Mol Cell Biol 26: 9413–9423.
25. Claassen GF, Hann SR. 1999. Myc-mediated transformation: The repression connection. Oncogene 18: 2925–2933.
26. Claassen GF, Hann SR. 2000. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor b-induced cell-cycle arrest. Proc Natl Acad Sci 97: 9498–9503.
27. Cole MD. 2014.MYC association with cancer risk and a new model of MYC-mediated repression. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014316.
28. Cole MD, Cowling VH. 2008. Transcription-independent functions of MYC: Regulation of translation and DNA replication. Nat Rev Mol Cell Biol 9: 810–815.
29. Conacci-Sorrell M, Ngouenet C, Eisenman RN. 2010. Mycnick: A cytoplasmic cleavage product of Myc that promotes a-tubulin acetylation and cell differentiation. Cell 142: 480–493.
30. Conacci-Sorrell M, McFerrin L, Eisenman RN. 2014. An overview of MYC and its interactome. Cold Spring Harb Perspect Med 4: 014357.
31. Conerly ML, Teves SS, Diolaiti D, Ulrich M, Eisenman RN, Henikoff S. 2010. Changes in H2A.Z occupancy and DNA methylation during B-cell lymphomagenesis. Genome Res 20: 1383–1390.
32. Corvetta D, Chayka O, Gherardi S, D’Acunto CW, Cantilena S, Valli E, Piotrowska I, Perini G, Sala A. 2013. Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: Functional and therapeutic implications. J Biol Chem 288: 8332– 8341.
33. Cotterman R, Jin VX, Krig SR, Lemen JM, Wey A, Farnham PJ, Knoepfler PS. 2008. N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res 68: 9654–9662.
34. Cowling VH, Cole MD. 2006.Mechanism of transcriptional activation by the Myc oncoproteins. Semin Cancer Biol 16: 242–252.
35. Cowling VH, Cole MD. 2008. An N-Myc truncation analogous to c-Myc-S induces cell proliferation independently of transactivation but dependent on Myc homology box II. Oncogene 27: 1327–1332.
36. Dai MS, Sears R, Lu H. 2007. Feedback regulation of c-Myc by ribosomal protein L11. Cell Cycle 6: 2735–2741.
37. Dang CV. 2012.MYCon the path to cancer. Cell 149: 22–35.
38. Datta A, Nag A, Pan W, Hay N, Gartel AL, Colamonici O, Mori Y, Raychaudhuri P. 2004.Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J Biol Chem 279: 36698–36707.
39. Davis AC, Wims M, Spotts GD, Hann SR, Bradley A. 1993. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev 7: 671–682.
40. de Nigris F, Botti C, Rossiello R, Crimi E, Sica V, Napoli C. 2007. Cooperation betweenMyc and YY1 provides novel silencing transcriptional targets of a3b1-integrin in tumour cells. Oncogene 26: 382–394.
41. Eberhardy SR, Farnham PJ. 2001. c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism. J Biol Chem 276: 48562–48571.
42. Eberhardy SR, Farnham PJ. 2002. Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. J Biol Chem 277: 40156–40162.
43. Egle A, Harris AW, Bouillet P, Cory S. 2004. Bim is a suppressor ofMyc-induced mouse B cell leukemia. Proc Natl Acad Sci 101: 6164–6169.
44. Eischen CM, Woo D, Roussel MF, Cleveland JL. 2001. Apoptosis triggered byMyc-induced suppression of Bcl-XL or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol 21: 5063–5070.
45. El-Osta A, Wolffe AP. 2000. DNA methylation and histone deacetylation in the control of gene expression: Basic biochemistry to human development and disease. Gene Expr 9: 63–75.
46. Elkon R, Zeller KI, Linhart C, Dang CV, Shamir R, Shiloh Y.2004. In silico identification of transcriptional regulators associated with c-Myc. Nucleic Acids Res 32: 4955–4961.
47. Farrell AS, Sears RC. 2014. MYC degradation. Cold Spring Harb Perspect Med 4: 014365.
48. Fazzio TG, Huff JT, Panning B. 2008. An RNAi screen of chromatin proteins identifies Tip60-p400 as a regulator of embryonic stem cell identity. Cell 134: 162–174.
49. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, et al. 2005. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391–400.
50. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B. 2001. Binding of c-Myc to chromatin mediates mitogeninduced acetylation of histone H4 and gene activation. Genes Dev 15: 2069–2082.
51. Frank SR, Parisi T, Taubert S, Fernandez P, Fuchs M, Chan HM, Livingston DM, Amati B. 2003. MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep 4: 575–580.
52. Fujii T, Ueda T, Nagata S, Fukunaga R. 2010. Essential role of p400/mDomino chromatin-remodeling ATPase in bone marrow hematopoiesis and cell-cycle progression. J Biol Chem 285: 30214–30223.
53. Gabay M, Li Y, Felsher DW. 2014. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014241.
54. Gartel AL, Ye X, Goufman E, Shianov P, Hay N,Najmabadi F, Tyner AL. 2001. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci 98: 4510–4515.
55. Geng F, Wenzel S, Tansey WP. 2012. Ubiquitin and proteasomes in transcription. Annu Rev Biochem 81: 177–201.
56. Gherardi S, Valli E, Erriquez D, Perini G. 2013. MYCNmediated transcriptional repression in neuroblastoma:The other side of the coin. Front Oncol 3: 42.
57. Gill RM, Gabor TV, Couzens AL, Scheid MP. 2013. The MYC-associated protein CDCA7 is phosphorylated by AKT to regulate MYC-dependent apoptosis and transformation. Mol Cell Biol 33: 498–513.
58. Gjerset RA. 2006. DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer. J Mol Histol 37: 239–251.
59. Gordan JD, Thompson CB, Simon MC. 2007. HIF and cMyc: Aibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12: 108–113.
60. Gorrini C, Squatrito M, Luise C, Syed N, Perna D, Wark L, Martinato F, Sardella D, Verrecchia A, Bennett S, et al. 2007. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 448: 1063–1067.
61. Grandori C, Eisenman RN. 1997. Myc target genes. Trends Biochem Sci 22: 177–181.
62. Grandori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, Galloway DA, Eisenman RN, White RJ. 2005. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol 7: 311–318.
63. Gregory MA, Qi Y, Hann SR. 2005. The ARF tumor suppressor: Keeping Myc on a leash. Cell Cycle 4: 249–252.
64. Grisendi S, Mecucci C, Falini B, Pandolfi PP. 2006. Nucleophosmin and cancer. Nat Rev Cancer 6: 493–505.
65. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W. 2001. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci 98: 5043– 5048.
66. Gu W, Bhatia K, Magrath IT, Dang CV, Dalla-Favera R. 1994. Binding and suppression of the Myc transcriptional activation domain by p107. Science 264: 251–254.
67. Guccione E, Martinato F, Finocchiaro G, Luzi L, Tizzoni L, Dall’ Olio V, Zardo G, Nervi C, Bernard L, Amati B. 2006. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol 8: 764-770.
68. Hann SR. 2006. Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. Semin Cancer Biol 16: 288–302.
69. Hann SR, Eisenman RN. 1984. Proteins encoded by the human c-myc oncogene: Differential expression in neoplastic cells. Mol Cell Biol 4: 2486–2497.
70. Hann SR, Abrams HD, Rohrschneider LR, Eisenman RN.1983. Proteins encoded by v-myc and c-myc oncogenes: Identification and localization in acute leukemia virus transformants and bursal lymphoma cell lines. Cell 34: 789–798.
71. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, Lowe SW. 2005. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436: 807–811.
72. Herkert B, Eilers M. 2010. Transcriptional repression: The dark side of myc. Genes Cancer 1: 580–586.
73. Herkert B, Dwertmann A, Herold S, Abed M, Naud JF, Finkernagel F, Harms GS, Orian A, Wanzel M, Eilers M. 2010. The Arf tumor suppressor protein inhibits Miz1 to suppress cell adhesion and induce apoptosis. J Cell Biol 188: 905–918.
74. Herold S, Wanzel M, Beuger V, Frohme C, Beul D, Hillukkala T, Syvaoja J, Saluz HP, Haenel F, Eilers M. 2002. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell 10: 509–521.
75. Hervouet E, Vallette FM, Cartron PF. 2009. Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation. Epigenetics 4: 487–499.
76. Hirst SK, Grandori C. 2000. Differential activity of conditional MYC and its variant MYC-S in human mortal fibroblasts. Oncogene 19: 5189–5197.
77. Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, Zatloukal K, Denk H. 2006. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 5: 2203–2210.
78. Huang W, Zhao S, Ammanamanchi S, Brattain M, Venkatasubbarao K, Freeman JW. 2005. Trichostatin A induces transforming growth factor b type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/ p300 to a Sp1.NF-Y complex. J Biol Chem 280: 10047-10054.
79. Hydbring P, Larsson LG. 2010. Cdk2: A key regulator of teh senescence control function of Myc. Aging (Albany NY) 2: 244–250.
80. Iraci N, Diolaiti D, Papa A, Porro A, Valli E, Gherardi S, Herold S, Eilers M, Bernardoni R, Della Valle G, et al. 2011. A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res 71: 404–412.
81. Iritani BM, Eisenman RN. 1999. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci 96: 13180–13185.
82. Jackstadt R, Jung P, Hermeking H. 2013. AP4 directly downregulates p16 and p21 to suppress senescence and mediate ransformation. Cell Death Dis 4: 775.
83. Ji H, Wu G, Zhan X, Nolan A, Koh C, De Marzo A, Doan HM, Fan J, Cheadle C, Fallahi M, et al. 2011. Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation. PLoS ONE 6: 26057.
84. Jiang G, Espeseth A, Hazuda DJ, Margolis DM. 2007. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 81: 10914–10923.
85. Jung P, Hermeking H. 2009. The c-MYC-AP4-p21 cascade. Cell Cycle 8: 982–989.
86. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, et al. 2007. CIP2A inhibits PP2A in human malignancies. Cell 130: 51–62.
87. Kasowski M, Grubert F, Heffelfinger C, Hariharan M, Asabere A, Waszak SM, Habegger L, Rozowsky J, Shi M, Urban AE, et al. 2010. Variation in transcription factor binding among humans. Science 328: 232–235.
88. Kaur M, Cole MD. 2013. MYC acts via the PTEN tumor suppressor to elicit autoregulation and genome-wide gene repression by activation of the Ezh2 methyltransferase. Cancer Res 73: 695–705.
89. Kenneth NS, Ramsbottom BA, Gomez-Roman N, Marshall L, Cole PA, White RJ. 2007. TRRAP and GCN5 are used by c-Myc to activate RNA polymerase III transcription. Proc Natl Acad Sci 104: 14917–14922.
90. Kiernan RE, Emiliani S, Nakayama K, Castro A, Labbe JC, Lorca T, Nakayama Ki K, Benkirane M. 2001. Interaction between cyclin T1 and SCFSKP2 targets CDK9 for ubiquitination and degradation by the proteasome. Mol Cell Biol 21: 7956–7970.
91. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. 2003. Skp2 regulates Myc protein stability and activity. Mol Cell 11: 1177–1188.
92. Kim J, Lee JH, Iyer VR. 2008. Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS ONE 3: 1798.
93. Knoepfler PS, Zhang XY, Cheng PF, Gafken PR, McMahon SB, Eisenman RN. 2006. Myc influences global chromatin structure. EMBO J 25: 2723–2734.
94. Knuesel MT, Meyer KD, Bernecky C, Taatjes DJ. 2009. The human CDK8 subcomplex is a molecular switch that controls Mediator coactivator function. Genes Dev 23: 439–451.
95. Koch HB, Zhang R, Verdoodt B, Bailey A, Zhang CD, Yates JR III, Menssen A, Hermeking H. 2007. Large-scale identification of c-MYC-associated proteins using a combined TAP/MudPIT approach. Cell Cycle 6: 205–217.
96. Kurland JF, Tansey WP. 2008.Myc-mediated transcriptional repression by recruitment of histone deacetylase. Cancer Res 68: 3624–3629.
97. Kurosu T, Peterlin BM. 2004. VP16 and ubiquitin; binding of P-TEFb via its activation domain and ubiquitin facilitates elongation of transcription of target genes. Curr Biol 14: 1112–1116.
98. Laurenti E, Varnum-Finney B, Wilson A, Ferrero I, Blanco-Bose WE, Ehninger A, Knoepfler PS, Cheng PF, Mac Donald HR, Eisenman RN, et al. 2008. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell 3: 611–624.
99. Lawlor ER, Soucek L, Brown-Swigart L, Shchors K, Bialucha CU, Evan GI. 2006. Reversible kinetic analysis of Myc targets in vivo provides novel insights intoMyc-mediated tumorigenesis. Cancer Res 66: 4591–4601.
100. Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR. 1997.Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 387: 422–426.
101. Leone G, Sears R, Huang E, Rempel R, Nuckolls F, Park CH, Giangrande P, Wu L, Saavedra HI, Field SJ, et al. 2001. Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell 8: 105–113.
102. Levens D. 2013.CellularMYCro economics: BalancingMYC function with MYC expression. Cold Spring Harb Perspect Med 3: 014233.
103. Li L, Davie JR. 2010. The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat 192: 275–283.
104. Li Z, Hann SR. 2009. The Myc-nucleophosmin-ARF network: A complex web unveiled. Cell Cycle 8: 2703–2707.
105. Li Z, Hann SR. 2013. Nucleophosmin is essential for c-Myc nucleolar localization and c-Myc-mediated rDNA transcription. Oncogene 32: 1988–1994.
106. Li LH, Nerlov C, Prendergast G, MacGregor D, Ziff EB. 1994. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. EMBO J 13: 4070–4079.
107. Li Z, Boone D, Hann SR. 2008. Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation. Proc Natl Acad Sci 105: 18794–18799.
108. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA. 2012. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151: 56–67.
109. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. 1995. A modified oestrogen receptor ligandbinding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 23: 1686– 1690.
110. Liu X, Tesfai J, Evrard YA, Dent SY, Martinez E. 2003. c-Myc transformation domain recruits the human STAGAcomplex and requires TRRAPand GCN5 acetylase activity for transcription activation. Mol Cell Biol 278: 20405–20412.
111. Liu T, Tee AE, Porro A, Smith SA, Dwarte T, Liu PY, Iraci N, Sekyere E, Haber M, Norris MD, et al. 2007. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl Acad Sci 104: 18682–18687.
112. Liu X, Vorontchikhina M, Wang YL, Faiola F, Martinez E. 2008. STAGA recruitsMediator to the MYC oncoprotein to stimulate transcription and cell proliferation. Mol Cell Biol 28: 108–121.
113. Lleonart ME, Vidal F, Gallardo D, Diaz-Fuertes M, Rojo F, Cuatrecasas M, Lopez-Vicente L, Kondoh H, Blanco C, Carnero A, et al. 2006. New p53 related genes in human tumors: Significant downregulation in colon and lung carcinomas. Oncol Rep 16: 603–608.
114. Loizou JI, Oser G, Shukla V, Sawan C, Murr R, Wang ZQ, Trumpp A, Herceg Z. 2009. Histone acetyltransferase cofactor Trrap is essential for maintaining the hematopoietic stem/progenitor cell pool. Mol Cell Biol 183: 6422–6431.
115. Luscher B, Vervoorts J. 2012. Regulation of gene transcription by the oncoprotein MYC. Mol Cell Biol 494: 145–160.
116. Lutterbach B, Hann SR. 1994. Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 14: 5510–5522.
117. Marshall GM, Gherardi S, Xu N, Neiron Z, Trahair T, Scarlett CJ, Chang DK, Liu PY, Jankowski K, Iraci N, et al. 2010. Transcriptional upregulation of histone deacetylase 2 promotesMyc-induced oncogenic effects. Oncogene 29: 5957–5968.
118. Martinato F, Cesaroni M, Amati B, Guccione E. 2008. Analysis of Myc-induced histone modifications on target chromatin. PLoS ONE 3: 3650.
119. Martinez-Cerdeno V, Lemen JM, Chan V, Wey A, Lin W, Dent SR, Knoepfler PS. 2012. N-Myc and GCN5 regulate significantly overlapping transcriptional programs in neural stem cells. PLoS ONE 7: 39456.
120. Matsuoka Y, Fukamachi K, Uehara N, Tsuda H, Tsubura A. 2008. Induction of a novel histone deacetylase 1/c-Myc/ Mnt/Max complex formation is implicated in parity-induced refractoriness to mammary carcinogenesis. Cancer Sci 99: 309–315.
121. Mattera L, Escaffit F, Pillaire MJ, Selves J, Tyteca S, Hoffmann JS, Gourraud PA, Chevillard-Briet M, Cazaux C, Trouche D. 2009. The p400/Tip60 ratio is critical for colorectal cancer cell proliferation through DNA damage response pathways. Oncogene 28: 1506–1517.
122. McMahon SB. 2014.MYC and the control of apoptosis. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect. a014407.
123. McMahon SB, Wood MA, Cole MD. 2000. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol 20: 556–562.
124. Meyer N, Penn LZ. 2008. Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976–990.
125. Minella AC, Clurman BE. 2005.Mechanisms of tumor suppression by the SCFFbw7. Cell Cycle 4: 1356–1359.
126. Muratani M, Tansey WP. 2003. How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 4: 192–201.
127. Murr R, Vaissiere T, Sawan C, Shukla V, Herceg Z. 2007. Orchestration of chromatin-based processes: Mind the TRRAP. Oncogene 26: 5358–5372.
128. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L, Casellas R, et al. 2012. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151: 68–79.
129. Niemela M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernila P, Kallioniemi OP, Joensuu H, Hautaniemi S, Westermarck J. 2012. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene 31: 4266–4278.
130. Nikiforov MA, Chandriani S, Park J, Kotenko I, Matheos D, Johnsson A, McMahon SB, Cole MD. 2002. TRRAP-dependent and TRRAP-independent transcriptional activation by Myc family oncoproteins. Mol Cell Biol 22: 5054–5063.
131. O’Donovan KJ, Diedler J, Couture GC, Fak JJ, Darnell RB. 2010. The onconeural antigen cdr2 is a novel APC/C target that acts in mitosis to regulate c-myc target genes in mammalian tumor cells. PLoS ONE 5: 10045.
132. Oster SK, Ho CS, Soucie EL, Penn LZ. 2002. The myc oncogene: MarvelouslY complex. Adv Cancer Res 84: 81-154.
133. Oster SK, Mao DY, Kennedy J, Penn LZ. 2003. Functional analysis of the N-terminal domain of the Myc oncoprotein. Oncogene 22: 1998–2010.
134. Pal S, Yun R, Datta A, Lacomis L, Erdjument-Bromage H, Kumar J, Tempst P, Sif S. 2003. mSin3A/histone deaetylase 2 and PRMT5-containing Brg1 complex is involved in transcriptional repression of the Myc target gene cad. Mol Cell Biol 23: 7475–7487.
135. Park J, Wood MA, Cole MD. 2002. BAF53 forms distinct nuclear complexes and functions as a critical c-Myc-interacting nuclear cofactor for oncogenic transformation. Mol Cell Biol 22: 1307–1316.
136. Patel JH, McMahon SB. 2006. Targeting of Miz-1 is essential for Myc-mediated apoptosis. J Biol Chem 281: 3283–3289.
137. Patel JH, McMahon SB. 2007. BCL2 is a downstream effector of MIZ-1 essential for blocking c-MYC-induced apoptosis. J Biol Chem 282: 5–13.
138. Perna D, Faga G, Verrecchia A, Gorski MM, Barozzi I, Narang V, Khng J, Lim KC, Sung WK, Sanges R, et al. 2012. Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts. Oncogene 31: 1695–1709.
139. Peukert K, Staller P, Schneider A, Carmichael G, Hanel F, Eilers M. 1997. An alternative pathway for gene regulation by Myc. EMBO J 16: 5672–5686.
140. Pineda-Lucena A, Ho CS, Mao DY, Sheng Y, Laister RC, Muhandiram R, Lu Y, Seet BT, Katz S, Szyperski T, et al. 2005. A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants. J Mol Biol 351: 182–194.
141. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, et al. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 92: 713–723.
142. Popov N, Wahlstrom T, Hurlin PJ, Henriksson M. 2005. Mnt transcriptional repressor is functionally regulated during cell cycle progression. Oncogene 24: 8326–8337.
143. Popov N, Schulein C, Jaenicke LA, Eilers M. 2010. Ubiquitylation of the amino terminus of Myc by SCFb-TrCP antagonizes SCFFbw7-mediated turnover. Nat Cell Biol 12: 973–981.
144. Qi Y, Gregory MA, Li Z, Brousal JP, West K, Hann SR. 2004. p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 431: 712–717.
145. Quintana AM, Liu F, O’Rourke JP, Ness SA. 2011. Identification and regulation of c-Myb target genes in MCF-7 cells. BMC Cancer 11: 30.
146. Rahl PB, Young RA. 2014. MYC and transcription elongation. Cold Spring Harb Perspect Med 4: 020990.
147. Rangasamy D. 2010. Histone variant H2A.Z can serve as a new target for breast cancer therapy. Curr Med Chem 17: 3155–3161.
148. Rempel RE, Mori S, Gasparetto M, Glozak MA, Andrechek ER, Adler SB, Laakso NM, Lagoo AS, Storms R, Smith C, et al. 2009. A role for E2F activities in determining the fate of Myc-induced lymphomagenesis. PLoS Genet 5: 1000640.
149. Rodriguez RM, Huidobro C, Urdinguio RG, Mangas C, Soldevilla B, Dominguez G, Bonilla F, Fernandez AF, Fraga MF. 2012. Aberrant epigenetic regulation of bromodomain BRD4 in human colon cancer. J Mol Med (Berl) 90: 587–595.
150. Sabó A, Amati B. 2014. Genome recognition by MYC. Cold Spring Harb Perspect Med 4: 014191.
151. Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC. 1996. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet 14: 69–77.
152. Sakuraba K, Yokomizo K, Shirahata A, Goto T, Saito M, Ishibashi K, Kigawa G, Nemoto H, Hibi K. 2011. TIP60 as a potential marker for the malignancy of gastric cancer. Anticancer Res 31: 77–79.
153. Sapountzi V, Logan IR, Robson CN. 2006.Cellular functions of TIP60. Int J Biochem Cell Biol 38: 1496–1509.
154. Satou A, Taira T, Iguchi-Ariga SM, Ariga H. 2001. A novel transrepression pathway of c-Myc. Recruitment of a transcriptional corepressor complex to c-Myc by MM-1, a c-Myc-binding protein. J Biol Chem 276: 46562–46567.
155. Schneider A, Peukert K, Eilers M, Hanel F. 1997. Association ofMyc with the zinc-finger protein Miz-1 defines a novel pathway for gene regulation by Myc. Curr Top Microbiol Immunol 224: 137–146.
156. Schuhmacher M, Staege MS, Pajic A, Polack A, Weidle UH, Bornkamm GW, Eick D, Kohlhuber F. 1999. Control of cell growth by c-Myc in the absence of cell division. Curr Biol 9: 1255–1258.
157. Secombe J, Eisenman RN. 2007. The function and regulation of the JARID1 family of histone H3 lysine 4 demethylases: The Myc connection. Cell Cycle 6: 1324–1328.
158. Seo HR, Kim J, Bae S, Soh JW, Lee YS. 2008. Cdk5-mediated phosphorylation of c-Myc on Ser-62 is essential in transcriptional activation of cyclin B1 by cyclin G1. J Biol Chem 283: 15601–15610.
159. Sherr CJ. 2006. Divorcing ARF and p53: An unsettled case. Nat Rev Cancer 6: 663–673.
160. Smith KN, Singh AM, Dalton S. 2010. Myc represses rimitive endoderm differentiation in pluripotent stem cells. Cell Stem Cell 7: 343–354.
161. Spotts GD, Patel SV, Xiao Q, Hann SR. 1997. Identification of downstream-initiated c-Myc proteins which are dominant negative inhibitors of transactivation by full-length c-Myc proteins. Mol Cell Biol 17: 1459–1468.
162. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, Moroy T, Bartek J, Massague J, Hanel F, et al. 2001. Repression of p15INK4b expression byMyc through association with Miz-1. Nat Cell Biol 3: 392–399.
163. Subtil-Rodriguez A, Reyes JC. 2011. To cross or not to cross the nucleosome, that is the elongation question. RNABiol 8: 389–393.
164. Takahashi H, Parmely TJ, Sato S, Tomomori-Sato C, Banks CA, Kong SE, Szutorisz H, Swanson SK, Martin-Brown S, Washburn MP, et al. 2011. Human mediator subunit MED26 functions as a docking site for transcription elongation factors. Cell 146: 92–104.
165. Thomas LR, Tansey WP. 2011. Proteolytic control of the oncoprotein transcription factor Myc. Nat Cell Biol 110: 77–106.
166. To KK, Huang LE. 2013. An efficient way of studying protein protein interactions involving HIF-a, c-Myc, and Sp1. Nat Cell Biol 1012: 77–84.
167. Uribesalgo I, Buschbeck M, Gutierrez A, Teichmann S, Demajo S, Kuebler B, Nomdedeu JF, Martin-Caballero J, Roma G, Benitah SA, et al. 2011. E-box-independent regulation of transcription and differentiation by MYC. Nat Cell Biol 13: 1443–1449.
168. Varlakhanova NV, Knoepfler PS. 2009. Acting locally and globally: Myc’s ever-expanding roles on chromatin. Nat Cell Biol 69: 7487–7490.
169. Vervoorts J, Luscher-Firzlaff JM, Rottmann S, Lilischkis R, Walsemann G, Dohmann K, Austen M, Luscher B. 2003. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep 4: 484–490.
170. Vervoorts J, Luscher-Firzlaff J, Luscher B. 2006. The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem 281: 34725–34729.
171. von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, Hydbring P, Weidung I, Nakayama K, Nakayama KI, et al. 2003. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 11: 1189–1200.
172. Wang X, Cunningham M, Zhang X, Tokarz S, Laraway B, Troxell M, Sears RC. 2011a. Phosphorylation regulates c-Myc’s oncogenic activity in the mammary gland. Cancer Res 71: 925–936.
173. Wang Z, Lin S, Li JJ, Xu Z, Yao H, Zhu X, Xie D, Shen Z, Sze J, Li K, et al. 2011b. MYC protein inhibits transcription of the microRNA cluster MC-let-7a-1_let-7d via noncanonical E-box. J Biol Chem 286: 39703–39714.
174. Welboren WJ, Sweep FC, Span PN, Stunnenberg HG. 2009. Genomic actions of estrogen receptor a: What are the targets and how are they regulated? Endocr Relat Cancer 16: 1073–1089.
175. Welcker M, Orian A, Grim JE, Eisenman RN, Clurman BE. 2004a. A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size. Curr Biol 14: 1852–1857.
176. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, Clurman BE. 2004b. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylationdependent c-Myc protein degradation. Proc Natl Acad Sci 101: 9085–9090.
177. Wiese KE, Walz S, von Eyss B, Wolf E, Athineos D, Sansom O, Eilers M. 2013. The role of MIZ1 in MYC-dependent tumorigenesis. Cold Spring Harb Perspect Med 3: 014290.
178. Winkler DD, Muthurajan UM, Hieb AR, Luger K. 2011. Histone chaperone FACT coordinates nucleosome Interaction through multiple synergistic binding events. J Biol Chem 286: 41883–41892.
179. Wittschieben BO, Fellows J, Du W, Stillman DJ, Svejstrup JQ. 2000. Overlapping roles for the histone acetyltransferase activities of SAGA and elongator in vivo. EMBO J 19: 3060–3068.
180. Wood MA, McMahon SB, Cole MD. 2000. An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. Mol Cell 5: 321–330.
181. Xiao Q, Claassen G, Shi J, Adachi S, Sedivy J, Hann SR. 1998. Transactivation-defective c-MycS retains the ability to regulate proliferation and apoptosis. Genes Dev 12: 3803–3808.
182. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K, Nakayama KI. 2004. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 23: 2116–2125.
183. Yang J, Chai L, Fowles TC, Alipio Z, Xu D, Fink LM, Ward DC, Ma Y. 2008. Genome-wide analysis reveals Sall4 to be a major regulator of pluripotency in murine-embryonic stem cells. Proc Natl Acad Sci 105: 19756–19761.
184. Yang J, Sung E, Donlin-Asp PG, Corces VG. 2013. A subset of Drosophila Myc sites remain associated with mitotic chromosomes colocalized with insulator proteins. Nat Commun 4: 1464.
185. Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, et al. 2012. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas. Cancer Cell 22: 506–523.
186. Zhang Q, Spears E, Boone DN, Li Z, Gregory MA, Hann SR. 2013. Domain-specific c-Myc ubiquitylation controls c-Myc transcriptional and apoptotic activity. Proc Natl Acad Sci 110: 978–983.
187. Zhao X, Heng JI, Guardavaccaro D, Jiang R, Pagano M, Guillemot F, Iavarone A, Lasorella A. 2008. The HECTdomain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein. Nat Cell Biol 10: 643–653.
188. Zhou X, Hao Q, Liao JM, Liao P, Lu H. 2013. Ribosomal protein S14 negatively regulates c-Myc activity. J Biol Chem 288: 21793–21801.
189. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424–2433.
190. Zippo A, De Robertis A, Serafini R, Oliviero S. 2007. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 9: 932–944.
191. Zou Y, Wu J, Giannone RJ, Boucher L, Du H, Huang Y, Johnson DK, Liu Y, Wang Y. 2008. Nucleophosmin/B23 negatively regulates GCN5-dependent histone acetylation and transactivation. J Biol Chem 283: 5728–5737.